About
Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies for genetically defined diseases. The company is known for its lead program, bezuclastinib, which targets specific mutations in the KIT receptor tyrosine kinase, with multiple NDAs pending review with the FDA.
Focus
Office
Lease
Markets
Headquarters
180 CityPoint
FAQs
Cogent Biosciences has financed 1 deal.
Cogent Biosciences's most recent deal was on October 01, 2025.
Member since: October 2025
Deals
Transaction Type
Asset Type
State
Sort By
LEASED
Cogent Biosciences Leases 31,518 Square Feet At BXP's 180 CityPoint In Waltham MA
180 Third Avenue, Waltham, MA
MACRE
Oct 1, 2025